Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Neoplasm Metastasis 4Pancreatic Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumors 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Endometrial Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-menopausal Breast Cancer 1Non-Small Cell Lunch Cancer 1Non Castrate Metastatic Prostate Cancer 1Neoplasms 1Nasopharyngeal Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Locally Advanced Solid Tumor 1

Interventions

Rituximab 16ibrutinib 9Bortezomib 8fludarabine phosphate 7Lenalidomide 6Cyclophosphamide 5Bendamustine Hydrochloride 5Peripheral Blood Stem Cell Transplantation 4Flow Cytometry 4Dasatinib 4tanespimycin 3pomalidomide 3belinostat 3Vorinostat 3Polymerase Chain Reaction 3Pharmacogenomic Testing 3Melphalan 3Everolimus 3Etoposide 3Dexamethasone 3ublituximab 2nelarabine 2ibritumomab tiuxetan 2fludarabine 2carfilzomib 2alvocidib 2Tacrolimus 2Methotrexate 2Magnetic Resonance Spectroscopy 2MLN 8237 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Waldenstrom Macroglobulinemia × NVP-BKM120 × Clear all
NCT02049541 2022-06-30

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
18 enrolled
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡